Long-lasting monoclonal antibodies are recommended to children ages 8 to 19 months old during their second respiratory syncytial virus season if they have underlying medical conditions.
The study, published in the journal Pediatrics, examined the direct medical costs of RSV-associated hospitalizations for young children, sorting the figures by specific underlying medical conditions. Researchers utilized surveillance data gathered by the New Vaccine Surveillance Network, analyzing records from children younger than 2 years old who were hospitalized with laboratory-confirmed RSV across six pediatric medical centers between December 1, 2016, and October 31, 2019. To reflect current economic realities, all direct medical costs were adjusted to 2025 dollars.
Out of 1,715 children hospitalized with the virus during the study window, 67.5% had no underlying medical conditions or history of prematurity. Yet among the remaining patients aged 6 to 11 months who did have underlying health issues, the financial burden varied wildly depending on the diagnosis.
Neurologic and Neuromuscular Disorders Drive Highest Costs
Infants and toddlers with neurologic or neuromuscular disorders faced the steepest bills, running 4.4 times the costs of children hospitalized without underlying conditions. These patients also endured the longest hospital stays, averaging 6.5 days, and showed a higher requirement for mechanical ventilation than their peers.
The pattern shifted slightly when looking at children in their second year of life. Median hospital costs hit their peak among patients with chronic lung disease. However, when total population costs were tallied up across the board, neurologic and neuromuscular conditions remained the most expensive category.
“The cost-benefit for RSV prophylaxis in children with UMCs, including those beyond current recommendations, may be even greater than predicted,” the authors of the study concluded.
These findings provide a granular look at how specific diagnoses amplify both the clinical and economic severity of respiratory syncytial virus in early childhood. As pediatric medical centers manage seasonal surges, the data offers a clearer metric for evaluating preventative treatments targeted at vulnerable populations.
